Supplementary

Table S1 The disposition status of the patients in various analyses populations

Populations and reason for discontinuation	DC60, n (%)	DC75, n (%)	Total, n (%)
ITT-1	188	187	375
EP-1	155 (82.4)	159 (85.0)	314 (83.7)
SP-1	188 (100.0)	186 (99.5)	374 (99.7)
ITT-2	90 (47.9)	94 (50.3)	184 (49.1)
EP-2	74 (39.4)	80 (42.8)	154 (41.1)
SP-2	87 (46.3)	92 (49.2)	179 (47.7)
Follow up patients after treatment completed	184 (97.9)	180 (96.3)	364 (97.1)
Patients have completed the study	31 (16.5)	18 (9.6)	49 (13.1)
Patients discontinuation	157 (83.5)	169 (90.4)	326 (86.9)
Major cause for study completion/discontinuation			
Complete according to study protocol	31 (16.5)	18 (9.6)	49 (13.1)
Adverse event	0	0	0
Death	137 (72.9)	139 (74.3)	276 (73.6)
Disease progression confirmed	0	0	
Treatment/procedure required by patient is against study protocol	0	0	0
Lost to follow up	16 (8.5)	23 (12.3)	39 (10.4)
Major study protocol violation	0	0	0
Informed consent withdrawn	4 (2.1)	6 (3.2)	10 (2.7)
Other	0	1 (0.5)	1 (0.3)

ITT, intent-to-treat population; EP, evaluable population; SP, safety population; -1, first-line therapy period; -2, maintenance therapy period; DC75, group assigned to receive docetaxel 75 mg/m^2 as first-line treatment; DC60, group assigned to receive docetaxel 60 mg/m^2 as first-line treatment.

http://dx.doi.org/10.21037/atm-20-8078

Table S2 Incidence of adverse events during the study period

Adverse events incidence	DC60 (N=188), n (%) n'	DC75 (N=186), n (%) n'	Total (N=374), n (%) n'	Docetaxel maintenance (N=118), n (%) n'	BSC (N=61), n (%) n'	Total (N=179), n (%) n'
All adverse events	86 (45.7) 660	89 (47.8) 738	175 (46.8) 1398	87 (73.7) 506	7 (11.5) 14	94 (52.5) 520
Serious adverse events [1]	4 (2.1) 4	7 (3.8) 10	11 (2.9) 14	6 (5.1) 8	0	6 (3.4) 8
Adverse events related to study treatment [2]	85 (45.2) 604	85 (45.7) 673	170 (45.5) 1277	84 (71.2) 454	2 (3.3) 4	86 (48.0) 458
Serious adverse events related to study treatment [3]	3 (1.6) 3	7 (3.8) 8	10 (2.7) 11	4 (3.4) 5	0	4 (2.2) 5
Adverse events which led to study discontinuation	0	2 (1.1) 3	2 (0.5) 3	5 (4.2) 7	0	5 (2.8) 7
Adverse events related to study treatment that lead to study discontinuation		1(0.5) 1	1(0.3) 1	4 (3.4) 5	0	4 (2.2) 5
Adverse events which led to death				1 (0.8) 1	0	1 (0.6) 1
Adverse event related to study treatment that led to death				0	0	0

AEs in the first-line treatment period were all AEs from screening to the end of pre-maintenance treatment (the day before second randomization). [1] Severe adverse events were AEs with a level of 3 or above graded by the NCI-CTC. If severity data was missing, calculated as level 4 "life-threatening". [2] AEs related to study treatment were all adverse events except those determined as "not related". [3] SAEs related to study treatment were all serious adverse events except those determined as "not related". DC75, group assigned to receive docetaxel 75 mg/m^2 as first-line treatment; DC60, group assigned to receive docetaxel 60 mg/m^2 as first-line treatment; BSC, best supportive care; NCI-CTC, National Cancer Institute Common Toxicity Criteria; N, number of patients included in each treatment group; n (%), number (percentage) of patients in a given category; n, number of adverse events.

http://dx.doi.org/10.21037/atm-20-8078